Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 3/2020

Open Access 01-09-2020 | Original Article

Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2020

Login to get access

Abstract

Purpose

The inclusion of the patient’s perspective has become increasingly important when reporting adverse events and may assist in management of toxicity. The relationship between drug exposure and toxicity can be quantified by combining Markov elements with pharmacometric models. A minimal continuous-time Markov model (mCTMM) was applied to patient-reported outcomes using hand–foot syndrome (HFS) induced by capecitabine anti-cancer therapy as an example.

Methods

Patient-reported HFS grades over time of 150 patients from two observational studies treated with oral capecitabine were analyzed using a mCTMM approach. Grading of HFS severity was based on the Common Terminology Criteria for Adverse Events. The model was evaluated by visual predictive checks (VPC). Furthermore, a simulation study of the probability of HFS severity over time was performed in which the standard dosing regimen and dose adjustments according to HFS severity were investigated.

Results

The VPC of the developed dose–toxicity model indicated an accurate description of HFS severity over time. Individual absolute daily dose was found to be a predictor for HFS. The simulation study demonstrated a reduction of severe HFS using the recommended dose adjustment strategy.

Conclusion

A minimal continuous-time Markov model was developed based on patient-reported severity of hand–foot syndrome under capecitabine. Thus, a modeling framework for patient-reported outcomes was created which may assist in the optimization of dosage regimens and adjustment strategies aiming at minimizing symptom burden during anti-cancer drug therapy.
Appendix
Available only for authorised users
Literature
13.
go back to reference Twelves C, Scheithauer W, McKendrick J, Seitz JF, van Hazel G, Wong A et al (2012) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23:1190–1197. https://doi.org/10.1093/annonc/mdr366PubMedCrossRef Twelves C, Scheithauer W, McKendrick J, Seitz JF, van Hazel G, Wong A et al (2012) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23:1190–1197. https://​doi.​org/​10.​1093/​annonc/​mdr366PubMedCrossRef
14.
go back to reference Scheithauer W, Blum J (2004) Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park, NY) 18:1161–1168 Scheithauer W, Blum J (2004) Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park, NY) 18:1161–1168
19.
go back to reference Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2018) NONMEM user's guides (1989–2018). Icon Development Solutions, Gaithersburg Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2018) NONMEM user's guides (1989–2018). Icon Development Solutions, Gaithersburg
Metadata
Title
Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach
Publication date
01-09-2020
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2020
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-020-04128-7

Other articles of this Issue 3/2020

Cancer Chemotherapy and Pharmacology 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine